The half-life of FGFR3 in Pa-treated KMS-11 cells was shorter than that in vehicle-treated controls (Figure 5, A and B), suggesting that Pa compromises FGFR3 stability in FGFR3-activated MM cells. This evidence concerns the gene FGFR3 and Miyoshi myopathy.